Home  |  Contact

UniProtKB/Swiss-Prot Q9HCC0: Variant p.Arg155Gln

Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial
Gene: MCCC2
Variant information

Variant position:  155
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Arginine (R) to Glutamine (Q) at position 155 (R155Q, p.Arg155Gln).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (Q)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  3-methylcrotonoyl-CoA carboxylase 2 deficiency (MCC2D) [MIM:210210]: An autosomal recessive disorder of leucine catabolism. The phenotype is variable, ranging from neonatal onset with severe neurological involvement to asymptomatic adults. There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine, usually in combination with a severe secondary carnitine deficiency. {ECO:0000269|PubMed:11170888, ECO:0000269|PubMed:11181649, ECO:0000269|PubMed:11406611, ECO:0000269|PubMed:16010683, ECO:0000269|PubMed:17968484, ECO:0000269|PubMed:21071250, ECO:0000269|PubMed:22150417, ECO:0000269|PubMed:22264772, ECO:0000269|PubMed:22642865, ECO:0000269|PubMed:25382614, ECO:0000269|PubMed:27601257}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In MCC2D; mild form.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  155
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  563
The length of the canonical sequence.

Location on the sequence:   ANDATVKGGAYYPVTVKKQL  R AQEIAMQNRLPCIYLVDSGG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ANDATVKGGAYYPVTVKKQLRAQEIAMQNRLPCIYLVDSGG

Mouse                         ANDATVKGGTYYPVTVKKHVRAQEIALQNRLPCIYLVDSGG

Rat                           ANDATVKGGTYYPVTVKKHVRAQEIALQNRLPCIYLVDSGG

Caenorhabditis elegans        ANDATVKGGTYYPITVKKHLRAQEIARENKLPCIYLVDSGG

Drosophila                    ANDATVKGGSYYPITVKKHLRAQEIAQENRLPCIYLVDSGG

Slime mold                    ANDSTVKGGTYFPITVKKHLRAQEIAQENNLPCIYLVDSGG

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 23 – 563 Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial
Domain 49 – 306 CoA carboxyltransferase N-terminal
Region 49 – 555 Carboxyltransferase
Modified residue 141 – 141 N6-succinyllysine


Literature citations

The molecular basis of human 3-methylcrotonyl-CoA carboxylase deficiency.
Baumgartner M.R.; Almashanu S.; Suormala T.; Obie C.; Cole R.N.; Packman S.; Baumgartner E.R.; Valle D.;
J. Clin. Invest. 107:495-504(2001)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANTS MCC2D GLN-99; GLN-155; LEU-173; CYS-193; ARG-310 AND MET-339;

3-Methylcrotonyl-CoA carboxylase deficiency: mutation analysis in 28 probands, 9 symptomatic and 19 detected by newborn screening.
Dantas M.F.; Suormala T.; Randolph A.; Coelho D.; Fowler B.; Valle D.; Baumgartner M.R.;
Hum. Mutat. 26:164-174(2005)
Cited for: VARIANTS MCC2D GLN-99; TRP-155; GLN-155; TYR-190; THR-268; ARG-282; ARG-310; PHE-375 AND VAL-456; CHARACTERIZATION OF VARIANTS TYR-190 AND ARG-352;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.